Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 90.53 4.05% 3.52
ICPT closed up 4.05 percent on Tuesday, April 23, 2019, on 73 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: May 6

*** please verify all earnings dates ***
5 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ICPT trend table...

Date Alert Name Type % Chg
Death Cross Bearish 0.00%
Slingshot Bearish Bearish Swing Setup 0.00%
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New Downtrend Bearish 4.05%
Hammer Candlestick Bullish 4.05%
Narrow Range Bar Range Contraction 4.05%
NR7 Range Contraction 4.05%
Lower Bollinger Band Walk Weakness 4.05%

Older signals for ICPT ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:

Profile
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.
Medical Specialties Diabetes Gastroenterology Hepatology Digestive Diseases Fibrosis Obeticholic Acid Primary Biliary Cholangitis
Is ICPT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Apr 22 Intercept And Obeticholic Acid In NASH: Singing The Blues
Apr 19 5 Top Pharmaceutical Stocks to Buy in 2019
Apr 18 Which NASH Powerhouse Will Come Out On Top?
Apr 16 3 Top Healthcare Stocks to Buy in April
Apr 15 Gilead to Collaborate with Novo Nordisk for NASH Treatment
Apr 15 Intercept: Bears Spike The Ball But May Not Have Even Scored
Apr 12 Intercept Pharmaceuticals (ICPT) Presents At EASL International Liver Congress 2019 - Slideshow
Apr 12 Why Intercept's Success Was a Big Disappointment
Apr 11 Why Intercept Pharmaceuticals, Weight Watchers International, and Canopy Growth Slumped Today
Apr 11 NASH players in the red as EASL announcements fail to excite investors
See more ICPT news...
Indicators
Indicator Value
52 Week High 133.74
52 Week Low 64.5
Average Volume 1,278,105
200-Day Moving Average 106.3281
50-Day Moving Average 105.8684
20-Day Moving Average 105.349
10-Day Moving Average 97.709
Average True Range 5.3654
ADX 26.12
+DI 19.045
-DI 36.0014
Chandelier Exit (Long, 3 ATRs ) 106.6438
Chandelier Exit (Short, 3 ATRs ) 101.1462
Upper Bollinger Band 128.8543
Lower Bollinger Band 81.8437
Percent B (%b) 0.18
BandWidth 44.623679
MACD Line -5.5687
MACD Signal Line -2.7684
MACD Histogram -2.8004
Fundamentals Value
Market Cap 2.27 Billion
Num Shares 25.1 Million
EPS -15.49
Price-to-Earnings (P/E) Ratio -5.84
Price-to-Sales 20.99
Price-to-Book 8.77
PEG Ratio -0.61
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 97.22
Resistance 3 (R3) 96.79 94.12 96.11
Resistance 2 (R2) 94.12 92.42 94.34 95.73
Resistance 1 (R1) 92.33 91.37 93.23 92.76 95.36
Pivot Point 89.66 89.66 90.11 89.88 89.66
Support 1 (S1) 87.87 87.96 88.77 88.30 85.70
Support 2 (S2) 85.20 86.91 85.42 85.33
Support 3 (S3) 83.41 85.20 84.96
Support 4 (S4) 83.84